Identifying modulators of hERG channel activity using the PatchXpress® planar patch clamp

Journal of Biomolecular Screening

Volumn 10, Issue 2, 2005, Pages 168-181

  Dubin, Adrienne E ^a,j   Nasser, Nadia ^a   Rohrbacher, Jutta ^b   Hermans, An N ^b   Marrannes, Roger ^c   Grantham, Christopher ^d   Van Rossem, Koen ^b,h   Cik, Miroslav ^e   Chaplan, Sandra R ^a   Gallacher, David ^b   Xu, Jia ^f   Guia, Antonio ^f   Byrne, Nicholas G ^g   Mathes, Chris ^g,i  

^a J/Johnson Pharmaceutical Res/Dev   (United States)

^b Center of Excellence for Cardiovascular Safety Research and Mechanistic Pharmacology   (Belgium)

^c CNS Pain and Alzheimer   (Belgium)

^d Psychiatry I   (Belgium)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f AVIVA Biosciences Corporation   (United States)

^g MOLECULAR DEVICES CORPORATION   (United States)

^h Barrier Therapeutics nv   (Belgium)

ⁱ Sophion Bioscience Inc   (United States)

^j LLC   (United States)

more..

Author keywords

Assay; Automation; Human ether a go go related gene potassium channel; Throughput; Voltage clamp

Indexed keywords

ASTEMIZOLE; CISAPRIDE; DOFETILIDE; FLUNARIZINE; KETOCONAZOLE; MIBEFRADIL; OXATOMIDE; PIMOZIDE; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; RADIOISOTOPE;

ACCURACY; ARTICLE; AUTOMATION; BINDING ASSAY; CELL STRAIN HEK293; CONCENTRATION RESPONSE; DEVICE; DRUG IDENTIFICATION; DRUG POTENCY; ELECTRIC POTENTIAL; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; ISOTOPE LABELING; PATCH CLAMP; PRIORITY JOURNAL; QUALITY CONTROL; WHOLE CELL; WHOLE CELL PATCH CLAMP;

CELL LINE; ELECTROPHYSIOLOGY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; INHIBITORY CONCENTRATION 50; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; REPRODUCIBILITY OF RESULTS;

EID: 20144389310     PISSN: 10870571     EISSN: None     Source Type: Journal    
DOI: 10.1177/1087057104272295     Document Type: Article

References (23)

1. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Eur J Physiol 1981;391:85-100.
2. Witchel HJ, Milnes JT, Mitcheson JS, Hancox JC: Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. J Pharmacol Toxicol Meth 2002;48:65-80.
3. Kr potassium channel. Cell 1995;81:299-307.
4. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al: Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for abroad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45.
5. Picard S, Lacroix P: QT interval prolongation and cardiac risk assessment for novel drugs. Curr Opin Invest Drugs 2003;4:303-308.
6. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N: Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002;25:263-286.
7. Dubin AE, Nasser N, Rohrbacher J, Hermans AN, Marrannes R, Grantham C, et al: hERG channel activity assayed with the PatchXpress® planar patch clamp. Paper presented at the Drug Discovery for Ion Channels IV Biophysical Society Satellite Meeting, Baltimore, MD, February 2004.
8. Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, et al: Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 1998;74:230-241.
9. Wildman SA, Crippen GM: Prediction of physiochemical parameters by atomic contributions. J Chem Inf Comput Sci 1999;39:868-873.
10. Marrannes R, De Prins E: Computer programs to facilitate the estimation of time-dependent drug effects on ion channels. Comput Meth Programs Biowed 2004;74:167-181.
11. 3B receptor subunit. J Biol Chem 1999;274:30799-30810.
12. Mitcheson JS: Drug binding to HERG channels: evidence for a "non-aromatic" binding site for fluvoxmine. Br J Pharmacol 2003;139:883-884.
13. Chouabe C, Drici M-D, Romey G, Barhanin J, Lazdunski M: HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol 1998;54:695-703.
14. Piper DR, Varghese A, Sanguinetti MC, Tristani-Firouzi M: Gating currents associated with intramembrane charge displacement in HERG potassium channels. Proc Natl Acad Sci USA 2003;100:10534-10539.
15. Wang J, Zhang Y, Wang H, Hon H, Nattel S, Yang B, et al: Potential mechanisms for the enhancement of HERG K+ channel function by phospholipid metabolites. Br J Pharmacol 2004;141:586-599.
16. Bian J, Cui J, McDonald TV: HERG K+ channel activity is regulated by changes in phosphatidyl inositol 4,5-bisphosphate. Circ Res 2001;89:1168-1176.
17. Marty A, Neher E: Tight-seal whole cell recording. In Sakmann B, Neher E (eds): Single-Channel Recording. 2nd ed. New York: Plenum, 1985:115-116.
18. Brueggemann A, George M, Klau M, Beckler M, Steindl J, Behrends JC, et al: Ion channel drug discovery and research: the automated nano-patch-clamp technology. Curr Drug Discovery Technol 2004;1:91-96.
19. Wood C, Williams C, Waldron GJ: Patch clamping by numbers. Drug Discovery Today 2004;9:434-441.
20. Zheng W, Kiss L: Screening technologies for ion channel targets in drug discovery. Am Pharm Rev 2003;6:85-92.
21. Kiss L, Bennett PB, Uebele VN, Koblan KS, Kane SA, Neagle B, et al: High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay Drug Dev Technol 2003;1:127-135.
22. Wang X, Li M: Automated electrophysiology: high throughput of art. Assay Drug Dev Technol 2003;1:695-708.
23. Xu J, Guia A, Rothwarf D, Huang M, Sithiphong K, Ouang J, et al: A benchmark study with SealChip planar patch-clamp technology. Assay Drug Dev Technol 2003;1:675-684.